India's Delhi High Court orders patent office to decide Novartis drug application within four months
Change
India's Delhi High Court ordered the Controller General of Patents, Designs and Trademarks to frame standard operating procedures and to decide Novartis AG's 2011 patent application for Ribociclib and all oppositions within four months.
Why it matters
The court ruling removes open-ended administrative delay by imposing enforceable deadlines and requiring formal procedures for patent disposal. Patent examination and opposition resolution must now be prioritised under a court-backed timetable rather than left to indefinite administrative timelines.
Implications
- • Patent examiners at India's patent office must re-sequence workloads and complete the Ribociclib examination and opposition processing to meet the court-mandated schedule.
- • The Controller General of Patents, Designs and Trademarks must draft and implement standard operating procedures that set fixed review deadlines and compliance steps.
Unlock the decision layer.
See what the change means — implications, exposure, timing — and ask AI about any brief instantly.
- Implications: What actually changes downstream.
- Who is affected: Which teams or operators are exposed.
- What to watch: Deadlines, triggers, and next moves.
- Ask AI: Clarify any brief instantly, in context.
14-day free trial. Full access. No credit card required.
Start free trial
Source
Topics